Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy

OBJECTIVES: For nearly 3 years, the monoclonal antibody dupilumab has been approved in Germany for the treatment of patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Although efficacy has been demonstrated in large double-blind, placebo-controlled clinical trials, few reports of real-...

Descripción completa

Detalles Bibliográficos
Autores principales: Albrecht, Tobias, Sailer, Martin M., Capitani, Flavia, van Schaik, Carolina, Löwenheim, Hubert, Becker, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2023
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206757/
https://www.ncbi.nlm.nih.gov/pubmed/37234094
http://dx.doi.org/10.1016/j.waojou.2023.100780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206757/
https://www.ncbi.nlm.nih.gov/pubmed/37234094
http://dx.doi.org/10.1016/j.waojou.2023.100780

Ejemplares similares